嗜碱性粒细胞活化
CD63
医学
金标准(测试)
前瞻性队列研究
激发试验
免疫学
内科学
免疫球蛋白E
病理
嗜碱性粒细胞
生物
生物化学
抗体
基因
小RNA
替代医学
微泡
作者
Jose A Céspedes,Ruben Fernandez-Santamaria,Adriana Ariza,Gador Bogas,Inmaculada Doña,Carmen Rondon,María L. Salas,M. Labella,Cecilia Frecha,Cristobalina Mayorga,María J Torres,Tahia D Fernández
出处
期刊:Allergy
[Wiley]
日期:2022-12-07
摘要
Amoxicillin (AX) combined or not with clavulanic acid (CLV) is frequently involved in IgE-mediated reactions. Drug provocation test (DPT) is considered as the gold standard for diagnosis, although contraindicated in high-risk patients. Basophil activation test (BAT) can help diagnose immediate reactions to beta-lactams, although controversy exists regarding the best activation marker. We have performed a real-life study in a prospective cohort to analyze the real value of BAT as diagnostic tool and the best activation marker, CD63 and CD203c, for the evaluation of immediate reactions to these drugs.We prospectively evaluated patients with a clinical suspicion of immediate reactions after AX or AX-CLV administration during a 6-year period. The allergological work-up was done following the EAACI recommendations. BAT was performed in all patients using CD63 and CD203c as activation markers.In AX-allergic patients, both activation markers, CD63 and CD203c, showed similar SE values (48.6% and 46.7%, respectively); however, specificity was of 81.1% and 94.6%, respectively, with CD203c showing good positive predictive value and like-hood ratio. In CLV-allergic patients, CD203c showed higher SE (50%) than CD63 (42.9%), maintaining the same value of SP (80%). Combining the results of both markers can slightly increase the sensitivity (51.4% for AX and 54.8% for CLV), although decreasing the specificity (79.7% and 73%, respectively). Interestingly, all patients with an anaphylactic shock showed a positive BAT to CLV using CD203c.BAT using CD203c showed a good confirmatory power, especially for AX allergy. Placing BAT as a first step in the diagnostic procedure can help reduce the need of performing a complete allergological work-up in 46.6% of patients, diminishing the risk of reinducing allergic reactions.
科研通智能强力驱动
Strongly Powered by AbleSci AI